Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | Director | June 27, 2022 | June 30, 2022 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 15, 2026 | May 16, 2026 |
| SOPHIRIS BIO INC.SPHS · Entity 152909 | Director | June 27, 2019 | June 28, 2019 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | June 24, 2022 | June 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date June 27, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-06-27 | Direct | 115,919 |
Reported balance
After 2022-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-27 · Grant · Acquired 115,919 · Balance 115,919 F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 93,750 |
Reported balance
After 2022-06-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-27 · Grant · Acquired 93,750 · Balance 93,750 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year. F5: Not applicable. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.
F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year.
F5: Not applicable.
PROTHENA CORP PUBLIC LTD CO
Report date May 15, 2026 · Filed May 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.76 · Expires 2036-05-15 | Direct | 27,000 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
SOPHIRIS BIO INC.
Report date June 27, 2019 · Filed June 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2029-06-26 | Direct | 20,000 |
Reported balance
After 2019-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-27 · Grant · Acquired 20,000 · Balance 20,000 F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program. F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program.
F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period.
Ultragenyx Pharmaceutical Inc.
Report date June 24, 2022 · Filed June 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,745 |
Reported balance
After 2022-06-24 transaction · row 1
1 source rowRow 1 · 2022-06-24 · Grant · Acquired 3,300 · Balance 17,745 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.57 · Expires 2032-06-24 | Direct | 6,245 |
Reported balance
After 2022-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-24 · Grant · Acquired 6,245 · Balance 6,245 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 3,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-08-11 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 37,203 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 27, 2018 Filed Jun 28, 2018 20:57 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001209191-18-039910 · doc4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-26 F1 · security: Granted pursuant to the Company's 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 21:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $80.69 | $0.00 |
DisclosureSEC source: 0001209191-18-038844 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-19 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 21:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038844 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 01:17 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000051 · wf-form4_152781583882201.xml · derivative · entry 4 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F5 · derivative.exercise_date: On May 31, 2017, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. F5 · derivative.expiration_date: On May 31, 2017, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 01:17 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-18-000051 · wf-form4_152781583882201.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 01:17 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000051 · wf-form4_152781583882201.xml · derivative · entry 3 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 01:17 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $81.53 | $0.00 |
DisclosureSEC source: 0001609351-18-000051 · wf-form4_152781583882201.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2028-05-29 F2 · derivative.exercise_date: 100% of the shares vest on the one-year anniversary of the grant date. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:16 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0000899243-18-013418 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual general meeting in 2019 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 14, 2018 Filed Oct 2, 2018 23:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 34,269 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-053459 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,269 Underlying: Ordinary Shares · 34,269 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On May 14, 2018, the Reporting Person was granted 34,269 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 14, 2018 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 14, 2018 Filed Oct 2, 2018 23:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (right to buy) · Derivative | 51,671 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001209191-18-053459 · doc4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,671 Underlying: Ordinary Shares · 51,671 shares Expires 2028-05-14 F1 · derivative.exercise_date: On May 14, 2018, the Reporting Person was granted an option to purchase 51,671 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 14, 2018 or (ii) the Issuer's annual general meeting of shareholders in 2019. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 23:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001209191-17-041470 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-06-22 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 23:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041470 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:07 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-17-000051 · wf-form4_149643401670056.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:07 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $50.93 | $0.00 |
DisclosureSEC source: 0001609351-17-000051 · wf-form4_149643401670056.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2027-05-30 F1 · derivative.exercise_date: 100% of the shares vest on the one-year anniversary of the grant date. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 20:33 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001209191-17-036794 · doc4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-29 F1 · security: Granted pursuant to the Company's 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document |
| May 18, 2017 Filed May 19, 2017 20:08 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $56.23 | $0.00 |
DisclosureSEC source: 0000899243-17-013904 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual general meeting in 2018 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:21 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 17,974 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033265 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,974 Underlying: Ordinary Shares · 17,974 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On May 15, 2017 the Reporting Person was granted 17,974 RSUs under the Plan. The RSUs vest in equal annual installments over a three year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 15, 2017 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:21 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (right to buy) · Derivative | 25,845 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-17-033265 · doc4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,845 Underlying: Ordinary Shares · 25,845 shares Expires 2027-05-15 F1 · derivative.exercise_date: On May 15, 2017, the Reporting Person was granted an option to purchase 25,845 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 15, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.